Ex-Metacrine chief Preston Klassen recharges at microRNA biotech; Allogene begins search for a CFO

→ Pre­ston Klassen has mapped out his next des­ti­na­tion as pres­i­dent and R&D chief of mi­croR­NA de­vel­op­er Reg­u­lus Ther­a­peu­tics. Klassen was the CEO of Metacrine, a biotech co-found­ed and chaired by Rich Hey­man that was en­snarled in tox­i­c­i­ty is­sues with its NASH pro­gram. Metacrine would hand out pink slips to half its work­force be­fore a merg­er with Equi­l­li­um that ul­ti­mate­ly didn’t ma­te­ri­al­ize. Ear­li­er, Klassen was CMO and US pres­i­dent of San­i­fit and then led R&D at Are­na Phar­ma­ceu­ti­cals. Reg­u­lus al­so wel­comed Al­ler­gan vet Cur­tis Mon­nig as VP of CMC, the same po­si­tion he pre­vi­ous­ly held at Jan­u­ary Ther­a­peu­tics.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN